These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 2078487)
1. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487 [TBL] [Abstract][Full Text] [Related]
2. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979 [TBL] [Abstract][Full Text] [Related]
3. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Jones M; Siracky J; Kelland LR; Harrap KR Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780 [TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318 [TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
7. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Goddard P; Valenti M; Kelland LR Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451 [TBL] [Abstract][Full Text] [Related]
8. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381 [TBL] [Abstract][Full Text] [Related]
9. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748 [TBL] [Abstract][Full Text] [Related]
10. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8). Jones AC; Wilson PA; Steel GG Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788 [TBL] [Abstract][Full Text] [Related]
11. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864 [TBL] [Abstract][Full Text] [Related]
13. In vitro testing of platinum-based drugs on a panel of human ovarian tumour cell lines. Garner CM; Hubbold LM; Chakraborti PR Br J Biomed Sci; 2002; 59(1):15-9. PubMed ID: 12000179 [TBL] [Abstract][Full Text] [Related]
14. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588 [TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. Sun X; Lou LG; Sui DH; Wu XH Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132 [TBL] [Abstract][Full Text] [Related]
16. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602 [TBL] [Abstract][Full Text] [Related]
17. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Goddard PM; Valenti MR; Harrap KR Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720 [TBL] [Abstract][Full Text] [Related]
18. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Boven E; Nauta MM; Schluper HM; Elferink F; van der Vijgh WJ; Pinedo HM Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1253-60. PubMed ID: 4076289 [TBL] [Abstract][Full Text] [Related]
19. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas. Rose WC; Basler GA In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379 [TBL] [Abstract][Full Text] [Related]
20. Platinum coordination complexes which circumvent cisplatin resistance. Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]